2. Academic Validation
  3. A dual chemodrug-loaded hyaluronan nanogel for differentiation induction therapy of refractory AML via disrupting lysosomal homeostasis

A dual chemodrug-loaded hyaluronan nanogel for differentiation induction therapy of refractory AML via disrupting lysosomal homeostasis

  • Sci Adv. 2025 Mar 28;11(13):eado3923. doi: 10.1126/sciadv.ado3923.
Shilin Xu 1,  Tao Wang 1,  Xuechun Hu 1,  Hong Deng 1 2,  Yiyi Zhang 1 2,  Lei Xu 3,  Yang Zeng 3,  Jia Yu 4,  Weiqi Zhang 1 2,  Lin Wang 4,  Haiyan Xu 1
Affiliations

Affiliations

  • 1 Department of Biomedical Engineering, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, PR China.
  • 2 State Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, PR China.
  • 3 Institute of Hematology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, PR China.
  • 4 State Key Laboratory of Common Mechanism Research for Major Disease, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
PMID: 40153509 DOI: 10.1126/sciadv.ado3923
Abstract

Relapsed/refractory acute myeloid leukemia (rrAML) is a malignant blood Cancer with an extremely poor prognosis, largely ascribed to the drug-resistant leukemia stem cells (LSCs). Most patients suffer from a risk of difficult-to-cure as well as severe systemic toxicity when receiving standard chemotherapies. As hyaluronic acid (HA) is a specific ligand of CD44 highly expressed by LSCs, we had HA self-assembled with cisplatin and daunorubicin to form a dual chemodrug nanogel (HA/Cis/Dau) to afford the targeted therapeutic interventions of rrAML. HA/Cis/Dau displayed an extra therapeutic function of inducing the granulocyte-monocyte differentiation in CD44+ rrAML cells, an rrAML mouse model, and primary blasts isolated from patients with AML. Unlike free drugs directly diffusing and killing rrAML cells, HA/Cis/Dau transported the drugs into lysosomes, causing lysosomal membrane permeabilization, ROS accumulation, and thus a metabolic reprogramming of the rrAML cells. Moreover, HA/Cis/Dau was featured with alleviated side effects, ease of preparation, and cost effectiveness, therefore holding great promises for the targeted treatment of rrAML.

Figures
Products